|
Market Report
|
Generic Strategies in Emerging Markets
The emerging markets are luring a growing number of pharma companies looking to compensate for the diminishing revenues in developed markets. Latin America and Central and Eastern Europe (CEE) are showing strong growth rates, proving to be lucrative targets for firms aiming to expand their foothold, initially as a generics player, but also providing a foundation for subsequent brand penetration.
|
|
Read more...
|
|
|
Market Report
|
Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
Over the past decade, vaccines have resurfaced as an attractive commercial proposition for Pharma. The developed world has been the initial focus of vaccine makers due to the better healthcare infrastructure and higher price levels. However, facing increasingly saturated markets in the West, companies are looking to expand into new geographies, such as Asia's emerging markets.
|
|
Read more...
|
|
|
Market Report
|
Influenza Vaccines and Antivirals - The pandemic's long-term impact
Fuelled by the pandemic flu threat, the influenza market has expanded rapidly in recent years. This growing commercial opportunity has encouraged companies to develop new technologies and increase manufacturing capacity for influenza vaccines and antivirals. The H1N1 pandemic will stimulate further growth, but also confronts industry and public health stakeholders with new challenges.
|
|
Read more...
|
|
|
Market Report
|
The Diabetes Market Outlook to 2011
The Diabetes Market Outlook to 2011 provides in-depth insights into new product launches, upcoming patent expiries and on-going clinical trials in order to predict changes in global market dynamics. Key R&D trends are analyzed and pipeline compounds of the top players are evaluated, enabling you to strengthen your position in the diabetes market and anticipate future product success.
|
|
Read more...
|
|
|
Market Report
|
Molecular Targeted Cancer Therapies - Leading companies will hold onto competitive advantage in high growth market
Molecular targeted cancer therapies are the biggest and fastest growing class of cancer drugs in terms of sales. As growth of revenues from cytotoxic therapies and antihormonal therapies has slowed and many key brands in these classes face imminent patent expiries, it is unsurprising that the major oncology companies have shifted their focus towards the molecular targeted cancer therapies market.
|
|
Read more...
|
|
|
Market Report
|
Top 20 Cancer Therapy Brands - Targeted therapies will drive market growth in the wake of the cytotoxic and antihormonal patent cliff
The cancer therapies market offers a high level of commercial reward to a handful of companies including Roche, Sanofi-Aventis, AstraZeneca, Novartis and Eli Lilly. Cancer therapy sales totaled over $38 billion in the seven major pharmaceutical markets in 2008, growing at a CAGR of 17.4% between 2005 and 2008.
|
|
Read more...
|
|
|
Market Report
|
Colorectal Cancer - Shaping the future dynamics of colorectal cancer management
Until a decade ago, 5FU/leucovorin formed the mainstay of colorectal cancer treatment but Camptosar and Eloxatin quickly established themselves as components of gold-standard therapy. The advent of Avastin and Erbitux heralded a new era in the disease management, and the emergence of other molecular targeted agents should further push survival to an unprecedented level in the coming years.
|
|
Read more...
|
|
|
Market Report
|
Community Antibacterials - Pipelines wither as generic tidal wave takes its toll
Datamonitor research points to this sector, beleaguered by patent expiries, barriers to market entry and uptake, becoming increasingly inclement towards branded drugs. Generic incursion has taken a heavy toll on the market at a number of levels. The volume of key brands facing generic competition makes it even harder for remaining products to court large revenues in the community sector.
|
|
Read more...
|
|
|
Market Report
|
Molecular systems to open new markets
As a result of the increasing switch from live-attenuated and killed whole-cell vaccines to subunit antigens, there is a need for novel antigen delivery technologies to improve vaccine efficacy and safety. This report assesses key strategies, technologies and products for vaccine antigen delivery. It provides an overview of opportunities and challenges for the sector and a future outlook.
|
|
Read more...
|
|
|
<< Start < Prev 1 2 3 4 5 6 7 8 9 10 Next > End >>
|
| Results 46 - 54 of 324 |
Farmavita.Net Journal 
